Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance
Reference number: TA218
Published: 23 March 2011

Myelodysplastic syndromes - azacitidine: Decision Support Unit review of Celgene's response to the post appeal ACD

Myelodysplastic syndromes - azacitidine: Decision Support Unit review of Celgene's response to the post appeal ACD

Myelodysplastic syndromes - azacitidine: Decision Support Unit review of Celgene's response to the post appeal ACD
17 February 2011
(211.39 Kb 1 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 16 February 2011